About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a company based in Boston (United States) founded in 2010. Rhythm Pharmaceuticals has raised $84 million across 9 funding rounds from investors including HHS, Ipsen and Orbimed. The company has 283 employees as of December 31, 2024. Rhythm Pharmaceuticals has completed 1 acquisition, including Xinvento. Rhythm Pharmaceuticals offers products and services including IMCIVREE and Clinical Trials.
- Headquarter Boston, United States
- Employees 283 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rhythm Pharmaceuticals, Inc.
-
Annual Revenue
$130.13 M (USD)68.06as on Dec 31, 2024
-
Net Profit
-$260.6 M (USD)-41.11as on Dec 31, 2024
-
EBITDA
-$263.94 M (USD)-44.55as on Dec 31, 2024
-
Total Equity Funding
$84 M (USD)
in 9 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Apr 01, 2024
-
Investors
HHS
& 9 more
-
Employee Count
283
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol RYTM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals offers a comprehensive portfolio of products and services, including IMCIVREE and Clinical Trials.
IMCIVREE is utilized as a treatment for rare obesity disorders associated with neuroendocrine diseases
Clinical trials are conducted by Rhythm Pharmaceuticals to advance treatments for hyperphagia and obesity
People of Rhythm Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has successfully raised a total of $84M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Ipsen and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Rhythm Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Xinvento.
Investment portfolio details for Rhythm Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for congenital hyperinsulinism are researched and developed.
|
Locked | Locked | 2021 | Locked |
Complete acquisition details for Rhythm Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Rhythm Pharmaceuticals
Detailed financials for Rhythm Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rhythm Pharmaceuticals Comparisons
Peer comparison for Rhythm Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rhythm Pharmaceuticals
Detailed competitors of Rhythm Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rhythm Pharmaceuticals
Complete news archive for Rhythm Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals was founded in 2010.
Rhythm Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
David Meeker is the current CEO of Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals is a funded company, having raised a total of $84M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Rhythm Pharmaceuticals is 283.
Annual revenue of Rhythm Pharmaceuticals is $130.13M as on Dec 31, 2024.
Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.
Rhythm Pharmaceuticals offers IMCIVREE and Clinical Trials.
Yes, Rhythm Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol RYTM.
Rhythm Pharmaceuticals has made 1 acquisition, including Xinvento.
Rhythm Pharmaceuticals has 10 investors. Key investors include HHS, Ipsen, Orbimed, The Michael J. Fox Foundation, and Perceptive Advisors.
The ticker symbol of Rhythm Pharmaceuticals is RYTM on NASDAQ.